Celularity/$CELU
1D1W1MYTD1Y5YMAX
About Celularity
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
- Ticker
- $CELU
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 115
- Headquarters
- Florham Park, United States
- Website
- www.celularity.com
Celularity Metrics
BasicAdvanced
$23M
-
-$3.59
0.54
-
Price and volume
Market cap
$23M
Beta
0.54
52-week high
$4.01
52-week low
$0.56
Average daily volume
77K
Financial strength
Current ratio
0.153
Quick ratio
0.135
Long term debt to equity
-155.175
Total debt to equity
-197.852
Interest coverage (TTM)
-8.79%
Profitability
EBITDA (TTM)
-54.013
Gross margin (TTM)
24.39%
Net profit margin (TTM)
-345.45%
Operating margin (TTM)
-223.72%
Effective tax rate (TTM)
-0.00%
Revenue per employee (TTM)
$230,000
Management effectiveness
Return on assets (TTM)
-30.93%
Return on equity (TTM)
634.16%
Valuation
Price to revenue (TTM)
0.772
Price to book
-0.61
Price to tangible book (TTM)
-0.43
Price to free cash flow (TTM)
-1.547
Free cash flow yield (TTM)
-64.66%
Free cash flow per share (TTM)
-0.518
Growth
Revenue change (TTM)
-51.03%
Earnings per share change (TTM)
35.60%
3-year revenue growth (CAGR)
13.88%
3-year earnings per share growth (CAGR)
55.70%
What the Analysts think about Celularity
Analyst ratings (Buy, Hold, Sell) for Celularity stock.
Celularity Financial Performance
Revenues and expenses
Celularity Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.